CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,434,265 | +48.3% | 552,598 | -10.1% | 0.00% | +50.0% |
| Q2 2023 | $11,079,525 | +32.6% | 614,846 | +18.2% | 0.00% | 0.0% |
| Q1 2023 | $8,354,379 | +242.4% | 520,198 | +290.2% | 0.00% | +100.0% |
| Q4 2022 | $2,439,683 | +1.3% | 133,316 | +8.7% | 0.00% | 0.0% |
| Q3 2022 | $2,409,000 | +32.6% | 122,668 | +25.9% | 0.00% | – |
| Q2 2022 | $1,817,000 | -25.2% | 97,453 | -11.9% | 0.00% | -100.0% |
| Q1 2022 | $2,428,000 | +38.9% | 110,603 | +79.8% | 0.00% | – |
| Q4 2021 | $1,748,000 | +49.8% | 61,520 | +11.0% | 0.00% | – |
| Q3 2021 | $1,167,000 | +1.7% | 55,425 | -8.8% | 0.00% | – |
| Q2 2021 | $1,147,000 | -38.7% | 60,805 | -50.3% | 0.00% | – |
| Q1 2021 | $1,870,000 | +3.4% | 122,352 | -4.5% | 0.00% | – |
| Q4 2020 | $1,809,000 | +13.8% | 128,182 | +26.4% | 0.00% | – |
| Q3 2020 | $1,589,000 | +545.9% | 101,392 | +622.0% | 0.00% | – |
| Q2 2020 | $246,000 | -77.5% | 14,043 | -80.7% | 0.00% | – |
| Q3 2019 | $1,093,000 | -75.8% | 72,640 | -59.9% | 0.00% | -100.0% |
| Q2 2019 | $4,525,000 | +1279.6% | 180,990 | +1157.7% | 0.00% | – |
| Q1 2019 | $328,000 | -0.3% | 14,391 | +31.1% | 0.00% | – |
| Q4 2018 | $329,000 | – | 10,974 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |